Cost-Effectiveness of Percutaneous Closure of the Left Atrial Appendage in Atrial Fibrillation Based on Results From PROTECT AF Versus PREVAIL. - sprookjes - yvandenbroek - TriplyDB

Cost-Effectiveness of Percutaneous Closure of the Left Atrial Appendage in Atrial Fibrillation Based on Results From PROTECT AF Versus PREVAIL.

Cost-Effectiveness of Percutaneous Closure of the Left Atrial Appendage in Atrial Fibrillation Based on Results From PROTECT AF Versus PREVAIL.

http://www.wikidata.org/entity/Q37015495

about

Cost-Effectiveness of Percutaneous Closure of the Left Atrial Appendage in Atrial Fibrillation Based on Results From PROTECT AF Versus PREVAIL.

http://www.wikidata.org/entity/Q37015495

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on June 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Cost-Effectiveness of Percutan ...... rom PROTECT AF Versus PREVAIL.

@en

Cost-Effectiveness of Percutan ...... rom PROTECT AF Versus PREVAIL.

@nl

type

label

Cost-Effectiveness of Percutan ...... rom PROTECT AF Versus PREVAIL.

@en

Cost-Effectiveness of Percutan ...... rom PROTECT AF Versus PREVAIL.

@nl

prefLabel

Cost-Effectiveness of Percutan ...... rom PROTECT AF Versus PREVAIL.

@en

Cost-Effectiveness of Percutan ...... rom PROTECT AF Versus PREVAIL.

@nl

P1433

Q37015495-DBA0B94D-0B31-4841-BA21-B11F129FAD31

P1476

Q37015495-969841F3-9F8D-4DCB-8539-962994625F73

P2093

Q37015495-51D3CA3A-2730-47DC-A2A7-FFCBC18EB061

Q37015495-561C4B16-43A9-48F1-98C7-A5321642BC71

Q37015495-59C86922-BFED-4E91-AB5D-86F78F2DD39F

Q37015495-6B1ADC37-6DB6-4EA7-A8FC-B604AEB31E6B

Q37015495-764CAC1E-2C91-44B0-9114-BB679F9692E3

Q37015495-81910AEF-DFFD-48DF-A4B0-A0DD855E5476

Q37015495-84F73294-3ACA-40B0-A7F1-381BB2C4C143

Q37015495-A2C38CCE-2FF5-484B-9A84-82677290E1A0

Q37015495-A6A9E31B-E8D5-44DF-83D9-F0D3EDA97C4C

Q37015495-AB462437-3070-4A45-8337-D3D7BB0113D4

P2860

Q37015495-05BE1503-10BB-46E6-B497-F8DC7E7D6E1E

Q37015495-0757E3E8-E0F7-4AAB-9E7D-5038A9E758B9

Q37015495-078949BC-DA4C-4E25-B340-F3A718FE159E

Q37015495-0E0AB654-05D0-4A63-AC69-AF13E74BCBC6

Q37015495-13E08F85-07CC-4CD5-9E53-0664CDEDD886

Q37015495-16EC53BC-1B2B-4D6E-802B-1F5933B907B3

Q37015495-190572DB-6A71-4E86-8026-6A88D59C10D4

Q37015495-1A007A7B-B3AE-4ACC-876E-F9170FDBA858

Q37015495-1B4A72D4-1D43-406D-B076-5A39DD7E68AB

Q37015495-1D2B2982-5C51-497E-83EE-A92CB80E1380

P31

Q37015495-2473E471-1634-402F-9FB9-1871052D3F51

P356

Q37015495-310E0BE4-7A57-4F18-95B5-F84F78A633AF

P433

Q37015495-BBDD76A7-8EC0-4759-8000-68028C4DA976

P478

Q37015495-26C25A9A-089A-4005-9CE1-DFE1C78233BC

P50

Q37015495-60FE1B32-8819-4AF2-8AD8-CD6D09CE9223

P577

Q37015495-66DA5238-1BAA-4364-B54F-4058EEE4E6DB

P698

Q37015495-95588FE1-7463-458C-96F9-ADF8CC1B35F4

P921

Q37015495-0A435412-3277-4145-B98E-88236428919E

P932

Q37015495-36ADDF8B-33E5-4E2B-8C48-7F7680259FBB

P356

CIRCEP.115.003407

P1433

Circulation: Arrhythmia and Electrophysiology

P1476

Cost-Effectiveness of Percutan ...... rom PROTECT AF Versus PREVAIL.

@en

P2093

Alan M Garber

http://www.w3.org/2001/XMLSchema#string

Alan S Go

http://www.w3.org/2001/XMLSchema#string

Amin Al-Ahmad

http://www.w3.org/2001/XMLSchema#string

David W Hutton

http://www.w3.org/2001/XMLSchema#string

Douglas K Owens

http://www.w3.org/2001/XMLSchema#string

Geoffrey D Barnes

http://www.w3.org/2001/XMLSchema#string

James V Freeman

http://www.w3.org/2001/XMLSchema#string

Mintu P Turakhia

http://www.w3.org/2001/XMLSchema#string

Paul A Heidenreich

http://www.w3.org/2001/XMLSchema#string

Paul J Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation

Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis

Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation

Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial

Dabigatran versus warfarin in patients with atrial fibrillation

Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation

Apixaban versus warfarin in patients with atrial fibrillation

Edoxaban versus warfarin in patients with atrial fibrillation

P31

scholarly article

P356

10.1161/CIRCEP.115.003407

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27307517

http://www.w3.org/2001/XMLSchema#string

P921

atrial fibrillation

P932

4911813

http://www.w3.org/2001/XMLSchema#string